Design of Insulin Variants for Improved Treatment of Diabetes - Peptide and Protein Design for Biopharmaceutical Applications - page 282

[147] P. H. Kvist, T. Iburg, M. Bielecki, M. Gerstenberg, T. Buch-Rasmussen,
E. Hasselager and H. E. Jensen, Biocompatibility of electrochemical glucose sensors
implanted in the subcutis of pigs, Diab. Tech. Ther ., 8, 463-475 (2006).
[148] A. Tura, A. Maran and G. Pacini, Non-invasive glucose monitoring: Assessment of
technologies and devices according to quantitative criteria, Diab. Res. Clin. Prac .,
77, 16-40 (2007).
[149] R. Badugu, J. R. Lakowicz and C. D. Geddes, A glucose-sensing contact lens: From
bench top to patient, Curr. Opin. Biotech ., 16, 100-107 (2005).
[150] P. Thoniyot, F. E. Cappuccio, S. Gamsey, D. B. Cordes, R. A. Wessling and
B. Singaram, Continuous glucose sensing with fluorescent thin-film hydrogels. 2.
Fiber optic sensor fabrication and in vitro testing, Diab. Tech. Ther ., 8, 279-287
(2006).
[151] M. Morishita and N. A. Peppas, Is the oral route possible for peptide and protein
drug delivery?, Drug Disc. Today , 11, 905-910 (2006).
[152] S. Clement, P. Dandona, J. G. Still and G. Kosutic, Oral modified insulin (HIM2) in
patients with type 1 diabetes mellitus: Results from a phase I/II clinical trial, Metab.
Clin. Exp ., 53, 54-58 (2004).
[153] C. Dunn and M. P. Curran, Inhaled human insulin (Exubera ) - A review of its use
in adult patients with diabetes mellitus, Drugs , 66, 1013-1032 (2006).
[154] D. R. Owens, J. Grimley and P. Kirkpatrick, Inhaled human insulin, Nat. Rev. Drug
Disc ., 5, 371-372 (2006).
[155] W. T. Cefalu, The new diabetes inhalers: New tools for the clinician, Curr. Diabetes
Rep ., 7, 165-167 (2007).
[156] S. Rossi, G. Sandri and C. Caramella, Buccal delivery systems for peptides: Recent
advances, Am. J. Drug Del ., 3, 215-225 (2005).
[157] M. Brackbill and R. Schuller, Oralin: Buccally absorbed insulin, Adv. Pharm .,
3, 5-13 (2005).
[158] M. Schlein, S. Ludvigsen, H. B. Olsen, A. S. Andersen, G. M. Danielsen and
N. C. Kaarsholm, Properties of small molecules affecting insulin receptor function,
Biochemistry , 40, 13520-13528 (2001).
[159] C. Pender, I. D. Goldfine, V. P. Manchem, J. L. Evans, W. R. Spevak, S. Shi, S. Rao,
S. Bajjalieh, B. A. Maddux and J. F. Youngren, Regulation of insulin receptor
function by a small molecule insulin receptor activator, J. Biol. Chem ., 277,
43565-43571 (2002).
[160] A. K. Srivastava and M. Z. Mehdi, Insulino-mimetic and anti-diabetic effects of
vanadium compounds, Diabetic Med ., 22, 2-13 (2005).
[161] B. Zhang, G. Salituro, D. Szalkowski, Z. H. Li, Y. Zhang, I. Royo, D. Vilella,
M. T. Diez, F. Pelaez, C. Ruby, R. L. Kendall, X. Z. Mao, P. Griffin, J. Calaycay,
J. R. Zierath, J. V. Heck, R. G. Smith and D. E. Moller, Discovery of a small molecule
insulin mimetic with antidiabetic activity in mice, Science , 284, 974-977 (1999).
[162] S. A. Qureshi, V. Ding, Z. Li, D. Szalkowski, D.E. Biazzo-Ashnault, D. Xie,
R. Saperstein, E. Brady, S. Huskey, X. Shen, K. Liu, L. Xu, G. M. Salituro, J. V.
Heck, D. E. Moller, A. B. Jones and B. B. Zhang, Activation of insulin signal transduc-
tion pathway and anti-diabetic activity of small molecule insulin receptor activators,
J. Biol. Chem ., 275, 36590-36595 (2000).
[163] M. G. Roper, W. j. Qian, B. B. Zhang, R. N. Kulkarni, C. R. Kahn and R. T. Kennedy,
Effect of the insulin mimetic L -783,281 on intracellular [Ca2 þ ] and insulin secretion
from pancreatic b-cells, Diabetes , 51, S43-S49 (2002).